This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Leerink Partners has launched the Center for Pharmacoeconomics, which is an effo...
European medicines agencies network strategy (EMANS) to 2028 webinar, Online, Eu...
European Medicines Agency post-authorisation procedural advice for users of the ...
Gilead Sciences has defied analysts’ expectations by passing on its chance to li...
European Medicines Agency post-authorisation procedural advice for users of the ...
Solid said that the first patients to receive its Duchenne gene therapy all prod...
Solid Biosciences has surged back into the Duchenne muscular dystrophy gene ther...
Gilead Sciences has defied analysts’ expectations by passing on its chance to li...
Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s ...
Massive federal health cuts, CDC data backup, and other essential health news st...
“The National Institutes of Health is not only the largest institution for biome...
Agenda of the CAT meeting 19-21 February 2025
Basilea Pharmaceutica has cited its “stringent risk-return criteria” as a reason...
Quick guide: How to search, view and download a Clinical Trial and a Clinical Tr...
Quick guide - Introduction: CTIS for SMEs and Academia - CTIS Training Programme...
FAQs: Introduction to the Clinical Trials Regulation (EU) No 536/2014 - CTIS Tra...
Referral: Finasteride- and dutasteride-containing medicinal products, finasterid...
Accessia Health helps ease the burden of managing a rare disease or chronic con...
Human medicines European public assessment report (EPAR): Onureg, azacitidine, D...
Basilea Pharmaceutica has cited its “stringent risk-return criteria” as a reason...
“A decade ago this past June, my sister died at the National Institutes of Healt...
The uncertainty around the spending freeze was an epiphany for some, a realizati...
XRHealth is acquiring RealizedCare, a company that couples immersive experiences...
Onureg : EPAR - Procedural steps taken and scientific information after the auth...